Therapure Biopharma awarded contract for DoD project

Therapure Biopharma, Inc., announced on Tuesday that it will be a subcontractor for DynPort Vaccine Company, LLC, as part of a contract with the U.S. Department of Defense to develop a countermeasure for organophosphorus nerve agent poisoning.

Therapure is a contract development and manufacturing organization of biotherapeutics. The contract awarded to DVC is a cost-plus-fixed-fee contract with a maximum value of $157.3 million.

Therapure will be responsible for process optimization as well as manufacturing all clinical and nonclinical materials in support of DVC's contract to create, evaluate and obtain the U.S. Food and Drug Administration approval for human plasma-derived butyrylcholinesterase, HuBChE. HuBChE is a blood plasma protein that binds with and deactivates nerve agents.

"We are delighted to partner with DVC to develop and manufacture medical counter measures for the US Department of Defense as part of a defense strategy against a wide range of nerve gases," Therapure President and CEO Nick Green said. "Therapure successfully completed a rigorous selection and approval process to serve as the manufacturing subcontractor under the prime contract, which is a testament to the Company's standards and capabilities in biomanufacturing. It is an honor to be part of this very critical initiative to protect US Servicemen and women."

Organizations in this Story

U.S. Department of Defense

Want to get notified whenever we write about U.S. Department of Defense ?
Next time we write about U.S. Department of Defense, we'll email you a link to the story. You may edit your settings or unsubscribe at any time.